Search Results

Abstract

OBJECTIVE To estimate the cost of a case of retained fetal membranes (RFM) for dairy herds in the United States.

DESIGN Deterministic computer-based spreadsheet analysis.

SAMPLE Inputs from published studies and reports.

PROCEDURES Economic losses attributable to RFM were direct (reduction in milk yield and longer interval until pregnancy) and indirect (increased risk of developing clinical disease and increased culling risk). Cost attributable to milk loss was calculated as the mean marginal loss of milk production for cows with RFM and cows with RFM complicated by metritis. Cost of the increased risk of developing clinical disease because of RFM was a product of the cost of each clinical disease and the risk of each clinical disease attributable to RFM. Cost attributable to reduced reproductive performance was a function of a longer interval until pregnancy, whereas cost for increased culling attributable to RFM was associated with the market value of cull cows and replacement heifers as well as herd turnover rate.

RESULTS Cost of a case of RFM determined by use of default inputs was $386 (reduction in milk yield, $287; increased time until pregnancy, $73; increased disease risk, $25; and increased culling risk, $1). Sensitivity analysis revealed that milk and feed prices were the most influential inputs.

CONCLUSIONS AND CLINICAL RELEVANCE Cost of a case of RFM, including uncomplicated cases, was substantial and comparable to that for other common clinical diseases during the transition period. Preventive measures during the nonlactating period should be considered to minimize the incidence of RFM.

Abstract

Objective—To evaluate efficacy of a recombinant Moraxella bovis pilin-cytotoxin-Moraxella bovoculi cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis (IBK).

Animals—107 beef steers.

Procedures—2 groups of calves were inoculated SC with an immunostimulating complex (ISCOM) matrix adjuvant (control group; n = 54) or a recombinant M bovis pilin-cytotoxin–M bovoculi cytotoxin subunit antigen with the ISCOM matrix adjuvant (vaccine group; 53); calves received booster injections 21 days later. Calves were examined once weekly for 16 weeks. Investigators and herd managers were not aware of the inoculum administered to each calf throughout the trial. Primary outcome of interest was the cumulative proportion of calves that developed IBK. Serum samples were obtained before inoculation (day 0) and on days 42 and 112. Serum hemolysin-neutralizing titers against native M bovis and M bovoculi cytotoxin were determined.

Results—No difference was detected between groups for the cumulative proportion of calves that developed IBK at weeks 8 and 16 after inoculation. Non–IBK-affected calves in the vaccine group had a significantly higher fold change in serum hemolysin-neutralizing titer against native M bovoculi cytotoxin from day 0 to 42 compared to control calves.

Conclusions and Clinical Relevance—The M bovis pilin-cytotoxin-M bovoculi cytotoxin subunit vaccine with the ISCOM matrix adjuvant was not effective at preventing naturally occurring IBK. It is likely that the incorporation of additional protective antigens in a recombinant Moraxella spp subunit vaccine will be required to yield a product that can be used for effective immunization of cattle against IBK.